Production (Stage)
Heron Therapeutics, Inc.
HRTX
$2.12
$0.020.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.21% | 19.13% | 4.38% | 13.42% | 17.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.21% | 19.13% | 4.38% | 13.42% | 17.07% |
| Cost of Revenue | -17.74% | -2.05% | -49.36% | -55.20% | -49.19% |
| Gross Profit | 30.29% | 33.24% | 379.24% | 1,412.20% | 450.78% |
| SG&A Expenses | -5.31% | 76.23% | -19.14% | -32.55% | -28.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.42% | 36.33% | -33.88% | -42.74% | -37.03% |
| Operating Income | 165.74% | -43.46% | 82.12% | 84.80% | 85.49% |
| Income Before Tax | 183.39% | 134.16% | 80.61% | 78.04% | 90.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 183.39% | 134.16% | 80.61% | 78.04% | 90.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 183.39% | 134.16% | 80.61% | 78.04% | 90.36% |
| EBIT | 165.74% | -43.46% | 82.12% | 84.80% | 85.49% |
| EBITDA | 190.17% | -41.27% | 83.98% | 86.07% | 87.30% |
| EPS Basic | 182.30% | 134.14% | 81.62% | 82.75% | 92.39% |
| Normalized Basic EPS | 181.68% | -25.82% | 81.63% | 82.74% | 92.37% |
| EPS Diluted | 147.85% | 134.14% | 81.62% | 82.75% | 92.39% |
| Normalized Diluted EPS | 164.12% | -25.82% | 81.63% | 82.74% | 92.37% |
| Average Basic Shares Outstanding | 1.52% | -0.03% | 5.41% | 27.22% | 26.80% |
| Average Diluted Shares Outstanding | 30.24% | -0.03% | 5.41% | 27.22% | 26.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |